| Q37119926 | A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection |
| Q45877084 | A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo |
| Q53689031 | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. |
| Q34359593 | A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity |
| Q34733934 | A novel TLR3 inhibitor encoded by African swine fever virus (ASFV). |
| Q36546351 | A virological view of innate immune recognition |
| Q39667525 | Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses |
| Q33558337 | Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models |
| Q42119008 | Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of Toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition |
| Q33602726 | Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu |
| Q36951557 | Both NK cell-intrinsic and -extrinsic STAT1 signaling are required for NK cell response against vaccinia virus. |
| Q39829133 | Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics |
| Q36276652 | CD8 marks a subpopulation of lung-derived dendritic cells with differential responsiveness to viral infection and toll-like receptor stimulation |
| Q34476278 | CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells |
| Q36139858 | Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses |
| Q35132019 | Contemplating the Importance of Toll-like Receptors I and II Regarding Human Viral Pathogenesis |
| Q37333955 | Conventional bone marrow-derived dendritic cells contribute to toll-like receptor-independent production of alpha/beta interferon in response to inactivated parapoxvirus ovis |
| Q36961137 | Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection. |
| Q36947039 | Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. |
| Q27306437 | Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C |
| Q38582090 | Developments in Viral Vector-Based Vaccines |
| Q40141904 | Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein |
| Q33543131 | Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection |
| Q39617666 | Evaluating vaccinia virus cytokine co-expression in TLR GKO mice. |
| Q38159802 | Evolution of oncolytic viruses: novel strategies for cancer treatment |
| Q34120821 | Functional divergence among CD103+ dendritic cell subpopulations following pulmonary poxvirus infection |
| Q54520826 | Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. |
| Q37564261 | Generating memory with vaccination |
| Q38032237 | Herpesviral infection and Toll-like receptor 2 |
| Q36330959 | High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination |
| Q37309932 | Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes |
| Q91709860 | ICOS deficiency hampers the homeostasis, development and function of NK cells |
| Q40297259 | IL-18-dependent NKG2D ligand upregulation on accessory cells is mediated by the PI3K/GSK-3 pathway. |
| Q34532114 | Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver |
| Q36339034 | Impact of infection or vaccination on pre-existing serological memory |
| Q37944321 | Innate immune recognition of poxviral vaccine vectors |
| Q33805229 | Innate immune recognition of viruses and viral vectors |
| Q24626598 | Innate immune sensing of DNA viruses |
| Q28389050 | Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome |
| Q37996164 | Innate immunity modulation in virus entry. |
| Q47550893 | Inter-individual variation in health and disease associated with pulmonary infectious agents |
| Q34982651 | Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. |
| Q33741907 | Involvement of TLR2 in recognition of acute gammaherpesvirus-68 infection |
| Q36807121 | Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines |
| Q39774023 | MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. |
| Q60911893 | Microbubble-mediated delivery of human adenoviruses does not elicit innate and adaptive immunity response in an immunocompetent mouse model of prostate cancer |
| Q40596089 | Microneedle-mediated delivery of viral vectored vaccines |
| Q38092466 | Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling |
| Q42910554 | Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses |
| Q37371743 | Modulation of TLR2 protein expression by miR-105 in human oral keratinocytes |
| Q58701885 | Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice |
| Q40255445 | Monocytic myeloid-derived suppressor cells regulate T-cell responses against vaccinia virus. |
| Q33565626 | Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments |
| Q37643755 | MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2 |
| Q90411103 | Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development |
| Q38961205 | Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways |
| Q36139822 | NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. |
| Q34195250 | NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus. |
| Q36433932 | Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection. |
| Q34999938 | Novel drugs targeting Toll-like receptors for antiviral therapy |
| Q38021271 | Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination |
| Q38450392 | Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans |
| Q37845399 | Oncolytic vaccinia virus for the treatment of cancer |
| Q92884435 | PARP-1 controls NK cell recruitment to the site of viral infection |
| Q24338129 | Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation |
| Q36909996 | Plasmid DNA and viral vector-based vaccines for the treatment of cancer |
| Q82674952 | Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis |
| Q43243071 | Priming of NK cell anti-viral effector mechanisms by direct recognition of human cytomegalovirus |
| Q33370547 | Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection |
| Q39209632 | Protein kinase C overexpression does not enhance immune-stimulatory surface markers of vaccinia-infected dendritic cells and DC cell lines |
| Q37766262 | Recent insights into the role of Toll-like receptors in viral infection |
| Q45394542 | Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help |
| Q43210885 | Regulation of maturation and activating potential in CD8+ versus CD8- dendritic cells following in vivo infection with vaccinia virus. |
| Q34380402 | Role of type I interferon receptor signaling on NK cell development and functions |
| Q36980878 | Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. |
| Q39113576 | Rotavirus NSP4 Triggers Secretion of Proinflammatory Cytokines from Macrophages via Toll-Like Receptor 2. |
| Q39228868 | Skin microbiome and mast cells. |
| Q37237637 | Suppression of TLR9 immunostimulatory motifs in the genome of a gammaherpesvirus |
| Q36532515 | Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection |
| Q84750042 | TLR2 joins the interferon gang |
| Q96639868 | TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis |
| Q34646268 | TRAM is required for TLR2 endosomal signaling to type I IFN induction |
| Q34909902 | Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer |
| Q36747524 | Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases |
| Q33584637 | Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice |
| Q34313957 | The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors |
| Q37265478 | The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus |
| Q37372907 | The amino acid sequences flanking an antigenic determinant can strongly affect MHC class I cross-presentation without altering direct presentation |
| Q38924552 | The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) |
| Q38048555 | The status of live viral vaccination in early life |
| Q42198267 | Theiler's virus infection induces TLR3-dependent upregulation of TLR2 critical for proinflammatory cytokine production |
| Q36849770 | Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines |
| Q27487393 | Toll-Like Receptors and Viruses: Induction of Innate Antiviral Immune Responses |
| Q39791660 | Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands |
| Q33778828 | Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA |
| Q34067537 | Toll-like receptor agonists: are they good adjuvants? |
| Q27011462 | Toll-like receptors in antiviral innate immunity |
| Q36898663 | Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response |
| Q36955494 | Transgenic expression of non-structural genes of Theiler's virus suppresses initial viral replication and pathogenesis of demyelination |
| Q37552015 | Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development |
| Q27478142 | Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity |
| Q33990693 | Type I interferons mediate the innate cytokine response to recombinant fowlpox virus but not the induction of plasmacytoid dendritic cell-dependent adaptive immunity |
| Q36611339 | Type I interferons: diversity of sources, production pathways and effects on immune responses |
| Q37513066 | Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection |
| Q37825528 | Use of defined TLR ligands as adjuvants within human vaccines. |
| Q37158473 | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer |
| Q42093151 | Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components |
| Q24315019 | Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation |
| Q36456487 | Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. |
| Q41941241 | Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways |
| Q35205757 | dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity |